http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002538135-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-56
filingDate 2000-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2002-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2002538135-A
titleOfInvention α-aminoacetic acid derivatives useful as α4β7 receptor antagonists
abstract (57) Abstract: Compounds that bind to the alpha 4 beta 7 integrin is disclosed. Certain of these compounds also leukocyte adhesion, inhibit leukocyte adhesion mediated by particularly alpha 4 beta 7 integrin. Such compounds are useful in mammalian patients (eg, humans) for inflammatory diseases (eg, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis) And myocardial ischemia). The compounds can also be administered for the treatment of inflammatory brain diseases (eg, multiple sclerosis).
priorityDate 1999-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID292385
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID17123
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25361
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54266
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID107393082
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421097
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID201758
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID8174
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7412
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID292385
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID201758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059971
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID22329
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100032965

Total number of triples: 48.